<DOC>
	<DOCNO>NCT00322387</DOCNO>
	<brief_summary>Patients multiple myeloma ( MM ) non-Hodgkin 's lymphoma ( NHL ) mobilize chemotherapy G-CSF plus plerixafor ( AMD3100 ) . The purpose protocol determine plerixafor give chemotherapy G-CSF mobilization regimen safe , increase circulating level peripheral blood stem cell ( PBSCs ) â‰¥ 2-fold apheresis , transplantation apheresis product successful , measured time engraftment polymorphonuclear leukocyte ( PMNs ) platelet ( PLTs ) .</brief_summary>
	<brief_title>Mobilization Stem Cells With Plerixafor , Chemotherapy G-CSF Multiple Myeloma Non-Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description>An open label , multi-center , phase 2 study conduct patient MM NHL treat peripheral blood stem cell ( PBSC ) autologous transplantation . The change standard care addition plerixafor mobilization regimen chemotherapy G-CSF . Patients first give mobilize regimen chemotherapy per local practice guideline G-CSF ( customary dos ) apheresis perform . After first apheresis , plerixafor give 10PM , 10-11 hour second apheresis next day morning second day , 6 hour second apheresis . The change patient 's peripheral CD34+ cell count plerixafor dose start apheresis measure . The apheresis yield Day 1 Day 2 compare . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria ( Abbreviated List ) : MM first partial response/complete response , first relapse , second partial/complete response NHL first second partial complete remission NHL patient bone marrow involvement &lt; 10 % follicular involvement MM patient stable disease &lt; 40 % bone marrow involvement No three prior regimens chemotherapy ( thalidomide Decadron consider chemotherapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 White blood cell count ( WBC ) &gt; 3.0 x 10^9/L Absolute neutrophil count &gt; 1.5 x 10^9/L Platelet count &gt; 100 x 10^9/L Exclusion Criteria ( Abbreviated List ) : Brain metastasis carcinomatous meningitis Hypercalcaemia [ &gt; 1 mg/dl upper limit normal ( ULN ) ] Cardiovascular disease include proven predisposition ventricular arrhythmia Acute Infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem cell mobilization</keyword>
</DOC>